findmyKOL
Clinical trialNCT04055844CompletedPhase 2Interventional

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

SponsorMasonic Cancer Center, University of MinnesotaEnrollment14Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloid and Monocytic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota, United States

  • Washington University Medical School

    St Louis, Missouri, United States

  • University of Rochester Medical Center

    Rochester, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Feb 2020
Primary completion
6 Sept 2022
Completion
6 Sept 2022
Last update posted
7 Nov 2023
Registered enrollment
14
Registry id
NCT04055844

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.